Linked Life Data

17562544

Source:http://linkedlifedata.com/resource/pubmed/id/17562544

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17562544rdf:typepubmed:Citationlld:pubmed
pubmed-article:17562544lifeskim:mentionsumls-concept:C0242957lld:lifeskim
pubmed-article:17562544lifeskim:mentionsumls-concept:C1512505lld:lifeskim
pubmed-article:17562544lifeskim:mentionsumls-concept:C0069515lld:lifeskim
pubmed-article:17562544lifeskim:mentionsumls-concept:C0140080lld:lifeskim
pubmed-article:17562544lifeskim:mentionsumls-concept:C0206364lld:lifeskim
pubmed-article:17562544lifeskim:mentionsumls-concept:C0028347lld:lifeskim
pubmed-article:17562544lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:17562544lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:17562544lifeskim:mentionsumls-concept:C1533157lld:lifeskim
pubmed-article:17562544pubmed:issue2lld:pubmed
pubmed-article:17562544pubmed:dateCreated2008-1-23lld:pubmed
pubmed-article:17562544pubmed:abstractTextWe have reported that nordihydroguaiaretic acid (NDGA) inhibits the tyrosine kinase activities of the IGF-1 receptor (IGF-1R) and the HER2 receptor in breast cancer cells. Herein, we studied the effects of NDGA on the growth of estrogen receptor (ER) positive MCF-7 cells engineered to overexpress HER2 (MCF-7/HER2-18). These cells are an in vitro model of HER2-driven, ER positive, tamoxifen resistant breast cancer. NDGA was equally effective at inhibiting the growth of both parental MCF-7 and MCF-7/HER2-18 cells. Half maximal effects for both cell lines were in the 10-15 microM range. The growth inhibitory effects of NDGA were associated with an S phase arrest in the cell cycle and the induction of apoptosis. NDGA inhibited both IGF-1R and HER2 kinase activities in these breast cancer cells. In contrast, Gefitinib, an epidermal growth factor receptor inhibitor but not an IGF-1R inhibitor, was more effective in MCF-7/HER2-18 cells than in the parental MCF-7 cells and IGF binding protein-3 (IGFBP-3) was more effective against MCF-7 cells compared to MCF-7/HER2-18. MCF-7/HER2-18 cells are known to be resistant to the effects of the estrogen receptor inhibitor, tamoxifen. Interestingly, NDGA not only inhibited the growth of MCF-7/HER2-18 on its own, but it also demonstrated additive growth inhibitory effects when combined with tamoxifen. These studies suggest that NDGA may have therapeutic benefits in HER2-positive, tamoxifen resistant, breast cancers in humans.lld:pubmed
pubmed-article:17562544pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:languageenglld:pubmed
pubmed-article:17562544pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:citationSubsetIMlld:pubmed
pubmed-article:17562544pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17562544pubmed:statusMEDLINElld:pubmed
pubmed-article:17562544pubmed:monthFeblld:pubmed
pubmed-article:17562544pubmed:issn1097-4644lld:pubmed
pubmed-article:17562544pubmed:authorpubmed-author:ShiryLauraLlld:pubmed
pubmed-article:17562544pubmed:authorpubmed-author:GoldfineIra...lld:pubmed
pubmed-article:17562544pubmed:authorpubmed-author:YoungrenJack...lld:pubmed
pubmed-article:17562544pubmed:authorpubmed-author:CampbellMicha...lld:pubmed
pubmed-article:17562544pubmed:authorpubmed-author:AllanGeoffrey...lld:pubmed
pubmed-article:17562544pubmed:authorpubmed-author:MadduxBetty...lld:pubmed
pubmed-article:17562544pubmed:authorpubmed-author:ZavodovskayaM...lld:pubmed
pubmed-article:17562544pubmed:authorpubmed-author:KernerJohn...lld:pubmed
pubmed-article:17562544pubmed:authorpubmed-author:HodgesLeslieLlld:pubmed
pubmed-article:17562544pubmed:authorpubmed-author:KushnerPeterPlld:pubmed
pubmed-article:17562544pubmed:copyrightInfo(c) 2007 Wiley-Liss, Inc.lld:pubmed
pubmed-article:17562544pubmed:issnTypeElectroniclld:pubmed
pubmed-article:17562544pubmed:day1lld:pubmed
pubmed-article:17562544pubmed:volume103lld:pubmed
pubmed-article:17562544pubmed:ownerNLMlld:pubmed
pubmed-article:17562544pubmed:authorsCompleteYlld:pubmed
pubmed-article:17562544pubmed:pagination624-35lld:pubmed
pubmed-article:17562544pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:meshHeadingpubmed-meshheading:17562544...lld:pubmed
pubmed-article:17562544pubmed:year2008lld:pubmed
pubmed-article:17562544pubmed:articleTitleNordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.lld:pubmed
pubmed-article:17562544pubmed:affiliationDiabetes and Endocrine Research, University of California, San Francisco/Mt. Zion Medical Center, San Francisco, California, USA.lld:pubmed
pubmed-article:17562544pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17562544pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:17562544pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17562544lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17562544lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17562544lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17562544lld:pubmed